期刊文献+

Postoperative biliary adverse events following orthotopic liver transplantation: Assessment with magnetic resonance cholangiography 被引量:12

Postoperative biliary adverse events following orthotopic liver transplantation: Assessment with magnetic resonance cholangiography
在线阅读 下载PDF
导出
摘要 Biliary adverse events following orthotopic liver transplantation (OLT) are relatively common and continue to be serious causes of morbidity, mortality, and transplant dysfunction or failure. The development of these adverse events is heavily influenced by the type of anastomosis during surgery. The low specificity of clinical and biologic findings makes the diagnosis challenging. Moreover, direct cholangiographic procedures such as endoscopic retrograde cholangiopancreatography and percutaneous transhepatic cholangiography present an inadmissible rate of adverse events to be utilized in clinically low suspected patients. Magnetic resonance (MR) maging with MR cholangiopancreatography is crucial in assessing abnormalities in the biliary system after liver surgery, including liver transplant. MR cholangiopancreatography is a safe, rapid, non-invasive, and effective diagnostic procedure for the evaluation of biliary adverse events after liver transplantation, since it plays an increasingly important role in the diagnosis and management of these events. On the basis of a recent systematic review of the literature the summary estimates of sensitivity and specificity of MR cholangiopancreatography for diagnosis of biliary adverse events following OLT were 0.95 and 0.92, respectively. It can provide a non-invasive method of imaging surgical reconstruction of the biliary anastomoses as well as adverse events including anastomotic and non-anastomotic strictures, biliary lithiasis and sphincter of Oddi dysfunction in liver transplant recipients. Nevertheless, conventional T2-weighted MR cholangiography can be implemented with T1-weighted contrast-enhanced MR cholangiography using hepatobiliary contrast agents (in particular using Gd-EOB-DTPA) in order to improve the diagnostic accuracy in the adverse events’ detection such as bile leakage and strictures, especially in selected patients with biliary-enteric anastomosis. Biliary adverse events following orthotopic liver transplantation(OLT) are relatively common and continue to be serious causes of morbidity, mortality, and transplant dysfunction or failure. The development of these adverse events is heavily influenced by the type of anastomosis during surgery. The low specificity of clinical and biologic findings makes the diagnosis challenging. Moreover, direct cholangiographic procedures such as endoscopic retrograde cholangiopancreatography and percutaneous transhepatic cholangiography present an inadmissible rate of adverse events to be utilized in clinically low suspected patients. Magnetic resonance(MR) maging with MR cholangiopancreatography is crucial in assessing abnormalities in the biliary system after liver surgery, including liver transplant. MR cholangiopancreatography is a safe, rapid, noninvasive, and effective diagnostic procedure for the evaluation of biliary adverse events after liver transplantation, since it plays an increasingly important role in the diagnosis and management of these events. Onthe basis of a recent systematic review of the literature the summary estimates of sensitivity and specificity of MR cholangiopancreatography for diagnosis of biliary adverse events following OLT were 0.95 and 0.92, respectively. It can provide a non-invasive method of imaging surgical reconstruction of the biliary anastomoses as well as adverse events including anastomotic and non-anastomotic strictures, biliary lithiasis and sphincter of Oddi dysfunction in liver transplant recipients. Nevertheless, conventional T2-weighted MR cholangiography can be implemented with T1-weighted contrast-enhanced MR cholangiography using hepatobiliary contrast agents(in particular using Gd-EOBDTPA) in order to improve the diagnostic accuracy in the adverse events' detection such as bile leakage and strictures, especially in selected patients with biliaryenteric anastomosis.
机构地区 [
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第32期11080-11094,共15页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献15

  • 1Gursimran Kochhar,Jose Mari Parungao,Ibrahim A Hanouneh,Mansour A Parsi.Biliary complications following liver transplantation[J].World Journal of Gastroenterology,2013,19(19):2841-2846. 被引量:49
  • 2Emmanuelle D Williams,Peter V Draganov.Endoscopic management of biliary strictures after liver transplantation[J].World Journal of Gastroenterology,2009,15(30):3725-3733. 被引量:21
  • 3Maria C Londoo,Domingo Balderramo,Andrés Cárdenas.Management of biliary complications after orthotopic liver transplantation:The role of endoscopy[J].World Journal of Gastroenterology,2008,14(4):493-497. 被引量:22
  • 4Thomas Pusi,Ulrich Beuers.Ursodeoxycholic acid treatment of vanishing bile duct syndromes[J].World Journal of Gastroenterology,2006,12(22):3487-3495. 被引量:18
  • 5Thomas Zoepf,Evelyn J. Maldonado-Lopez,Philip Hilgard,Alexander Dech■ne,Massimo Malago,Christoph E. Broelsch,Joerg Schlaak,Guido Gerken.Diagnosis of biliary strictures after liver transplantation:Which is the best tool?[J].World Journal of Gastroenterology,2005,11(19):2945-2948. 被引量:32
  • 6Jennifer E. Jorgensen,Akbar K. Waljee,Michael L. Volk,Christopher J. Sonnenday,Grace H. Elta,Mahmoud M. Al-Hawary,Amit G. Singal,Jason R. Taylor,B. Joseph Elmunzer.Is MRCP equivalent to ERCP for diagnosing biliary obstruction in orthotopic liver transplant recipients? A meta-analysis[J].Gastrointestinal Endoscopy.2011(5)
  • 7A. Pecchi,M. De Santis,M.C. Gibertini,G. Tarantino,G.E. Gerunda,P. Torricelli,F. Di Benedetto.Role of Magnetic Resonance Imaging in the Detection of Anastomotic Biliary Strictures After Liver Transplantation[J].Transplantation Proceedings.2011(4)
  • 8Devasenathipathy Kandasamy,Raju Sharma,Ashu Seith Bhalla,Shivanand R. Gamanagatti,Deep N. Srivastava,Peush Sahni,Rakesh Kumar.MR evaluation of biliary-enteric anastomotic stricture: Does contrast-enhanced T1W MRC provide additional information?[J].Clinics and Research in Hepatology and Gastroenterology.2011(8)
  • 9Hidemasa Takao,Hiroyuki Akai,Taku Tajima,Shigeru Kiryu,Yasushi Watanabe,Hiroshi Imamura,Masaaki Akahane,Naoki Yoshioka,Norihiro Kokudo,Kuni Ohtomo.MR imaging of the biliary tract with Gd-EOB-DTPA: Effect of liver function on signal intensity[J].European Journal of Radiology.2009(2)
  • 10Rossano Girometti,Lorenzo Cereser,Giuseppe Como,Chiara Zuiani,Massimo Bazzocchi.Biliary complications after orthotopic liver transplantation: MRCP findings[J].Abdominal Imaging.2008(5)

二级参考文献168

  • 1[18]Heuman DM,Mills AS,McCall J,Hylemon PB,Pandak WM,Vlahcevic ZR.Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts.In vivo studies in the rat.Gastroenterology 1991; 100:203-211
  • 2[19]Heuman DM,Pandak WM,Hylemon PB,Vlahcevic ZR.Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts:in vitro studies in rat hepatocytes and human erythrocytes.Hepatology 1991; 14:920-926
  • 3[20]Ohiwa T,Katagiri K,Hoshino M,Hayakawa T,Nakai T.Tauroursodeoxycholate and tauro-beta-muricholate exert cytoprotection by reducing intrahepatocyte taurochenodeoxycholate content.Hepatology 1993; 17:470-476
  • 4[21]Deroubaix X,Coche T,Depiereux E,Feytmans E.Saturation of hepatic transport of taurocholate in rats in vivo.Am J Physiol1991; 260:G189-G196
  • 5[22]Galan AI,Jimenez R,Munoz ME,Gonzalez J.Effects of ursodeoxycholate on maximal biliary secretion of bilirubin in the rat.Biochem Pharmacol 1990; 39:1175-1180
  • 6[23]Jazrawi RP,de Caestecker JS,Goggin PM,Britten AJ,Joseph AE,Maxwell JD,Northfield TC.Kinetics of hepatic bile acid handling in cholestatic liver disease:effect of ursodeoxycholic acid.Gastroenterology 1994; 106:134-142
  • 7[24]Poupon RE,Chretien Y,Poupon R,Paumgartner G.Serum bile acids in primary biliary cirrhosis:effect of ursodeoxycholic acid therapy.Hepatology 1993; 17:599-604
  • 8[25]Heathcote EJ,Cauch-Dudek K,Walker V,Bailey RJ,Blendis LM,Ghent CN,Michieletti P,Minuk GY,Pappas SC,Scully LJ.The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.Hepatology 1994; 19:1149-1156
  • 9[26]Lindor KD.Ursodiol for primary sclerosing cholangitis.Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.N Engl J Med 1997; 336:691-695
  • 10[27]Poupon RE,Balkau B,Eschwege E,Poupon R.A multicenter,controlled trial of ursodiol for the treatment of primary biliary cirrhosis.UDCA-PBC Study Group.N Engl J Med 1991; 324:1548-1554

共引文献132

同被引文献91

引证文献12

二级引证文献126

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部